Exploration of Molecular Network Variations in Different Subtypes of Human Non-functional Pituitary Adenomas.
作者信息
Zhan Xianquan, Long Ying
机构信息
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital, Central South University, Changsha, China; State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, China; The State Key Laboratory of Medical Genetics, Central South University, Changsha, China.
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, China; Hunan Engineering Laboratory for Structural Biology and Drug Design, Xiangya Hospital, Central South University, Changsha, China; State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, China.
出版信息
Front Endocrinol (Lausanne). 2016 Feb 10;7:13. doi: 10.3389/fendo.2016.00013. eCollection 2016.
Abstract
摘要
相似文献
1
Exploration of Molecular Network Variations in Different Subtypes of Human Non-functional Pituitary Adenomas.
Front Endocrinol (Lausanne). 2016 Feb 10;7:13. doi: 10.3389/fendo.2016.00013. eCollection 2016.
2
Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.
Front Endocrinol (Lausanne). 2016 May 31;7:54. doi: 10.3389/fendo.2016.00054. eCollection 2016.
3
Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses.
Cancer Res. 2005 Nov 15;65(22):10214-22. doi: 10.1158/0008-5472.CAN-05-0884.
4
Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.
BMC Med Genomics. 2014 Dec 24;7:69. doi: 10.1186/s12920-014-0069-6.
5
Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas.
Electrophoresis. 2014 Aug;35(15):2184-94. doi: 10.1002/elps.201300590.
6
Comparative proteomics analysis of human pituitary adenomas: current status and future perspectives.
Mass Spectrom Rev. 2005 Nov-Dec;24(6):783-813. doi: 10.1002/mas.20039.
7
Somatostatin receptor subtype gene expression in pituitary adenomas.
J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92. doi: 10.1210/jcem.80.4.7714115.
8
[New medical treatments in pituitary adenomas].
Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S16-28. doi: 10.1016/S0003-4266(08)73964-7.
9
Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma.
Chin Med Sci J. 2004 Sep;19(3):199-202.
10
Differential gene expression in pituitary adenomas by oligonucleotide array analysis.
Eur J Endocrinol. 2005 Jul;153(1):143-51. doi: 10.1530/eje.1.01937.
引用本文的文献
1
Three-dimensional chromatin landscapes in somatotroph tumour.
Clin Transl Med. 2024 May;14(5):e1682. doi: 10.1002/ctm2.1682.
2
Applications of spatially resolved omics in the field of endocrine tumors.
Front Endocrinol (Lausanne). 2023 Jan 10;13:993081. doi: 10.3389/fendo.2022.993081. eCollection 2022.
3
Integration of quantitative phosphoproteomics and transcriptomics revealed phosphorylation-mediated molecular events as useful tools for a potential patient stratification and personalized treatment of human nonfunctional pituitary adenomas.
EPMA J. 2020 Aug 13;11(3):419-467. doi: 10.1007/s13167-020-00215-0. eCollection 2020 Sep.
4
Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes.
EPMA J. 2020 May 28;11(2):289-309. doi: 10.1007/s13167-020-00209-y. eCollection 2020 Jun.
5
Label-free quantitative identification of abnormally ubiquitinated proteins as useful biomarkers for human lung squamous cell carcinomas.
EPMA J. 2020 Jan 4;11(1):73-94. doi: 10.1007/s13167-019-00197-8. eCollection 2020 Mar.
6
Editorial: Molecular Network Study of Pituitary Adenomas.
Front Endocrinol (Lausanne). 2020 Feb 18;11:26. doi: 10.3389/fendo.2020.00026. eCollection 2020.
7
Quantitative Analysis of Proteome in Non-functional Pituitary Adenomas: Clinical Relevance and Potential Benefits for the Patients.
Front Endocrinol (Lausanne). 2019 Dec 5;10:854. doi: 10.3389/fendo.2019.00854. eCollection 2019.
8
Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas.
Front Endocrinol (Lausanne). 2019 Dec 17;10:835. doi: 10.3389/fendo.2019.00835. eCollection 2019.
9
The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas.
Front Endocrinol (Lausanne). 2019 May 22;10:330. doi: 10.3389/fendo.2019.00330. eCollection 2019.
本文引用的文献
1
EPMA position paper in cancer: current overview and future perspectives.
EPMA J. 2015 Apr 15;6(1):9. doi: 10.1186/s13167-015-0030-6. eCollection 2015.
2
Proteomic and functional profiles of a follicle-stimulating hormone positive human nonfunctional pituitary adenoma.
Electrophoresis. 2015 Jun;36(11-12):1289-304. doi: 10.1002/elps.201500006.
3
Transition From Microscopic to Endoscopic Transsphenoidal Surgery for Nonfunctional Pituitary Adenomas.
World Neurosurg. 2015 Jul;84(1):48-57. doi: 10.1016/j.wneu.2015.02.024. Epub 2015 Feb 28.
4
A new initiative on precision medicine.
N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.
5
Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.
BMC Med Genomics. 2014 Dec 24;7:69. doi: 10.1186/s12920-014-0069-6.
6
Identification of the proteomic variations of invasive relative to non-invasive non-functional pituitary adenomas.
Electrophoresis. 2014 Aug;35(15):2184-94. doi: 10.1002/elps.201300590.
7
Pituitary adenoma nitroproteomics: current status and perspectives.
Oxid Med Cell Longev. 2013;2013:580710. doi: 10.1155/2013/580710. Epub 2013 Mar 7.
8
Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor α-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells.
Endocrinology. 2013 Apr;154(4):1414-23. doi: 10.1210/en.2012-2128. Epub 2013 Mar 5.
9
Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer.
EPMA J. 2013 Jan 22;4(1):2. doi: 10.1186/1878-5085-4-2.
10
The use of variations in proteomes to predict, prevent, and personalize treatment for clinically nonfunctional pituitary adenomas.
EPMA J. 2010 Sep;1(3):439-59. doi: 10.1007/s13167-010-0028-z. Epub 2010 Jun 29.
Zotero 插件